Literature DB >> 23117396

Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.

Elizabeth C Miller1, Nicole M Chase, Peter Densen, Mary K Hintermeyer, James T Casper, John P Atkinson.   

Abstract

C3 deficiency is a rare disorder that leads to recurrent pyogenic infections. Here we describe a previously healthy 18 y/o Caucasian male with severe meningococcal disease. Total hemolytic activity was zero secondary to an undetectable C3. The C3 gene was normal by sequencing. Mixing the patient's serum with normal human serum led to C3 consumption. An IgG autoantibody in the patient's serum was identified that stabilized the classical pathway C3 and C5 convertases, thus preventing decay of these enzyme complexes. This autoantibody is an example of a C4 nephritic factor, with an additional feature of stabilizing the C5 convertase. Previous patients with C4 nephritic factor had membranoproliferative glomerulonephritis. Two years after presentation, this patient's C3 remains undetectable with no evidence of renal disease. We revisit the role of autoantibodies to classical pathway convertases in disease, review the literature on C4-NeF and comment on its detection in the clinical laboratory.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117396      PMCID: PMC3501611          DOI: 10.1016/j.clim.2012.09.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  21 in total

Review 1.  Complement driven by conformational changes.

Authors:  Piet Gros; Fin J Milder; Bert J C Janssen
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

3.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

Authors:  L Halbwachs; M Leveillé; P Lesavre; S Wattel; J Leibowitch
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

4.  C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.

Authors:  Y Tanuma; H Ohi; S Watanabe; M Seki; M Hatano
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes; A Cats
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

6.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 7.  Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H.

Authors:  E S Reis; D A Falcão; L Isaac
Journal:  Scand J Immunol       Date:  2006-03       Impact factor: 3.487

Review 8.  Complement deficiency states and meningococcal disease.

Authors:  J Figueroa; J Andreoni; P Densen
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 9.  C3 nephritic factor and SLE: report of four cases and review of the literature.

Authors:  M J Walport; K A Davies; M Botto; M A Naughton; D A Isenberg; D Biasi; R J Powell; N T Cheung; G R Struthers
Journal:  QJM       Date:  1994-10

10.  Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.

Authors:  Lisa Kuttner-Kondo; Dennis E Hourcade; Vernon E Anderson; Nasima Muqim; Lynne Mitchell; Dinesh C Soares; Paul N Barlow; M Edward Medof
Journal:  J Biol Chem       Date:  2007-03-29       Impact factor: 5.157

View more
  13 in total

1.  C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

Authors:  Yuzhou Zhang; Nicole C Meyer; Fernando C Fervenza; Winnie Lau; Adam Keenan; Gabriel Cara-Fuentes; Dingwu Shao; Aalia Akber; Veronique Fremeaux-Bacchi; Sanjeev Sethi; Carla M Nester; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2017-08-24       Impact factor: 8.860

Review 2.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

3.  Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.

Authors:  M Kathryn Liszewski; Martin Kolev; Gaelle Le Friec; Marilyn Leung; Paula G Bertram; Antonella F Fara; Marta Subias; Matthew C Pickering; Christian Drouet; Seppo Meri; T Petteri Arstila; Pirkka T Pekkarinen; Margaret Ma; Andrew Cope; Thomas Reinheckel; Santiago Rodriguez de Cordoba; Behdad Afzali; John P Atkinson; Claudia Kemper
Journal:  Immunity       Date:  2013-12-05       Impact factor: 31.745

Review 4.  Meningococcal Vaccinations.

Authors:  Nancy Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2016-04-16

Review 5.  Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.

Authors:  Katherine E Lintner; Yee Ling Wu; Yan Yang; Charles H Spencer; Georges Hauptmann; Lee A Hebert; John P Atkinson; C Yung Yu
Journal:  Front Immunol       Date:  2016-02-15       Impact factor: 7.561

Review 6.  Factor B and C4b2a Autoantibodies in C3 Glomerulopathy.

Authors:  Jill J Hauer; Dingwu Shao; Yuzhou Zhang; Carla M Nester; Richard J H Smith
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

Review 7.  Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.

Authors:  Fernando Corvillo; Marcin Okrój; Pilar Nozal; Marta Melgosa; Pilar Sánchez-Corral; Margarita López-Trascasa
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

8.  C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.

Authors:  Nóra Garam; Zoltán Prohászka; Ágnes Szilágyi; Christof Aigner; Alice Schmidt; Martina Gaggl; Gere Sunder-Plassmann; Dóra Bajcsi; Jürgen Brunner; Alexandra Dumfarth; Daniel Cejka; Stefan Flaschberger; Hana Flögelova; Ágnes Haris; Ágnes Hartmann; Andreas Heilos; Thomas Mueller; Krisztina Rusai; Klaus Arbeiter; Johannes Hofer; Dániel Jakab; Mária Sinkó; Erika Szigeti; Csaba Bereczki; Viktor Janko; Kata Kelen; György S Reusz; Attila J Szabó; Nóra Klenk; Krisztina Kóbor; Nika Kojc; Maarten Knechtelsdorfer; Mario Laganovic; Adrian Catalin Lungu; Anamarija Meglic; Rina Rus; Tanja Kersnik-Levart; Ernesta Macioniene; Marius Miglinas; Anna Pawłowska; Tomasz Stompór; Ludmila Podracka; Michael Rudnicki; Gert Mayer; Jana Reiterova; Marijan Saraga; Jakub Zieg; Eva Sládková; Tamás Szabó; Andrei Capitanescu; Simona Stancu; Miroslav Tisljar; Kresimir Galesic; András Tislér; Inga Vainumäe; Martin Windpessl; Tomas Zaoral; Galia Zlatanova; Dorottya Csuka
Journal:  Orphanet J Rare Dis       Date:  2019-11-08       Impact factor: 4.123

9.  Complement-related proteins control the flavivirus infection of Aedes aegypti by inducing antimicrobial peptides.

Authors:  Xiaoping Xiao; Yang Liu; Xiaoyan Zhang; Jing Wang; Zuofeng Li; Xiaojing Pang; Penghua Wang; Gong Cheng
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

10.  Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.

Authors:  Anna M Blom; Fernando Corvillo; Michal Magda; Grzegorz Stasiłojć; Pilar Nozal; Miguel Ángel Pérez-Valdivia; Virginia Cabello-Chaves; Santiago Rodríguez de Córdoba; Margarita López-Trascasa; Marcin Okrój
Journal:  J Clin Immunol       Date:  2016-05-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.